In addition, piR-2158 is downregulated in human and rodent breast cancer tumors and inhibits interleukin-11 (IL-11) expression by competing with FOS-related antigen 1 (FOSL1), inactivates the JAK/STAT pathway, and suppresses cell proliferation, migration, epithelial–mesenchymal transition (EMT), stemness, and angiogenesis [18]. Here, PIR is linked to breast carcinoma.